1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J Clin 2008; 58: 71–96.
3. Davydov MI, Axel EM. Cancer morbidity in Russia and CIS population in 2006. Vestnik RONC im.NN Blokhina RAMN 2008; 19 (Suppl. 1): 52–90.
4. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009; 112: 265–74.
5. du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCOC 2004). Ann Oncol 2005; 16 (Suppl 8): viii7–viii12.
6. Guppy AE, Nathan PD, Rustin GJ: Epithelial ovarian cancer: a review of current management. Clin Oncol 2005; 17: 399–411.
7. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6.
8. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18: 106–15.
9. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699–708.
10. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194–200.
11. Aravantinos G, Fountzilas G, Bamias A et al. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer 2008; 44: 2169–77.
12. Pignata S, Breda E, Scambia G et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol 2008; 66: 229–36.
13. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320–9.
14. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89–93.
15. Friedlander M, Millward MJ, Bell D et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998; 9: 1343–5.
16. von Minkwitz G, Bauknecht T, Visseren-Crul CM, Neijt IP. Phase II study of Gemcitabine in ovarian cancer. Ann Oncol 1999; 10: 853–5.
17. van Moorsel CJ, Veerman G, Vermorken JB et al. Mechanisms of synergism between gemcitabine and cisplatin. Adv Exp Med Biol 1998; 431: 581–5.
18. Vogt W, Bulankin A, Muller T et al. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 2000; 6: 2087–93.
19. Bozas G, Bamias A, Koutsoukou V et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynec Oncol 2007; 104: 580–5.
20. Papadimitriou CA, Fountzilas G, Aravantinos G et al. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group study. Gynecol Oncol 2004; 92: 152–9.
21. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699–707.
22. Kose F, Sufliarsky J, Beslija S T et al. Gemcitabine (G) plus carboplatin (C) in patients whose epithelial ovarian carcinomas (EOC) relapsed ≥6 months after platinum-containing first-line therapy: preliminary results of a phase II study. EJC Suppl. 1(5): S53, 2003, abstract 165.
23. du Bois A, Luck HJ, Pfisterer J et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer – a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Oncologie (AGO) Ovarian Cancer Study Group. Am Oncol 2001; 12: 1115–20.
24. Rose PG, Mossbruger K, Fusco N et al. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003; 88: 17–21.
25. Nagourney RA, Brewer CA, Radecki S et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2002; 88: 35–9.
26. Bauknecht T, Hefti A, Morack G et al. Gemcitabine combined with cisplatin as first-line in patients 60 years or older with epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer 2003; 13: 130–7.
27. Belpomme D, Krakowski I, Beauduin M et al. Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study. Gynecol Oncol 2003; 91: 32–8.
28. Nogue M, Cirera L, Arcusa M et al. Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anticancer Drugs 2002; 13: 839–45.
29. Krakowski I, Petit T, Kaytalire L et al. Gemcitabine in combination with cisplatin in advanced ovarian cancer: a phase II study. Proc Am Soc Clin Oncol 1998; 17: A1373,.
30. Ruiz G, Alexander F, Rodriguez G et al. Gemcitabine plus cisplatin as first line therapy for advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 2002; 21: A852.
31. Shaharyar, Shami N, Mahmood I et al. A phase II trial of gemcitabine and cisplatin combination chemotherapy in advanced epithelial ovarian cancer with bulky residual disease. Proc Am Soc Clin Oncol 2002; 21: A2518.
32. Suprasert P, Srisomboon J, Phongnarisorn C et al. A prospective phase II study of gemcitabine-cisplatin as first-line chemotherapy in advanced epithelial ovarian and fallopian tube cancer. Proc Am Soc Clin Oncol 2003; 22: A1917.
33. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16,.
34. CTC Investigator Guide, Version 2.0. Cancer Therapy Evaluation Program 1998. http://ctep.cancer.gov
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
36. Leemis L, Trivedi K. A comparison of approximate interval for the binomial parameters. Am Stat 1996; 50: 63–8.
37. Fruscella E, Gallo D, Ferrandina G et al. Gemcitabine: current role and future options in the treatment of ovarian cancer. Crit Rev Oncol Hematol 2003; 48: 81–8.
38. Poveda A. Gemcitabine in patients with ovarian cancer. Cancer Treat Rev 2005; 31 (Suppl 4): S29–S37.
39. Vergote I, van Corp T, Cadron I et al. Improving outcome in the first-line management of advanced ovarian cancer. EJC 2007; 1 (Suppl. 5): 23–8.

В.А.Горбунова1, Н.В.Коваленко2, Е.В.Шевякова2, Е.А.Готовкин3, А.С.Лисянская4, В.В.Дворниченко5, М.Ю.Бяхов6, И.Н.Петухова1

1 Российский онкологический научный центр им. Н.Н.Блохина, Москва;
2 Областной клинический онкологический диспансер, Ставрополь;
3 Областной клинический онкологический диспансер, Иваново;
4 Городской клинический онкологический диспансер, Санкт-Петербург;
5 Областной клинический онкологический диспансер, Иркутск;
6 Центральная клиническая больница №2 им. Н.А.Семашко МПС, Москва